Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The quantification of infarct size.

Raymond J Gibbons1, Uma S Valeti, Philip A Araoz

  • 1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA. gibbons.raymond@mayo.edu

Journal of the American College of Cardiology
|October 19, 2004
PubMed
Summary

Quantifying infarct size is crucial for evaluating new acute myocardial infarction therapies. Technetium-99m sestamibi SPECT imaging is currently the most validated method for measuring infarct size in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarkers for Immune Checkpoint Inhibitor-Induced Myocarditis: Caution Needed.

JACC. CardioOncology·2023
Same author

Type 2 Myocardial Infarction: Do We Need Risk Scores?

Journal of the American College of Cardiology·2023
Same author

Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations.

Biomedicines·2022
Same author

Artificial intelligence-augmented electrocardiography for left ventricular systolic dysfunction in patients undergoing high-sensitivity cardiac troponin T.

European heart journal. Acute cardiovascular care·2022
Same author

Measuring copeptin, a surrogate for vasopressin in patients with hypertension - Can it identify those who are volume Responsive?

Clinical biochemistry·2022
Same author

Implementation of High-Sensitivity Cardiac Troponin Assays in the United States.

Journal of the American College of Cardiology·2022

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Radiology

Background:

  • Accurate measurement of infarct size is vital for assessing novel therapies in acute myocardial infarction.
  • Current methods include serum markers, SPECT imaging, and MRI, each with varying degrees of validation.
  • The goal is to identify a reliable surrogate endpoint for early treatment efficacy evaluation.

Purpose of the Study:

  • To summarize published evidence on infarct size measurement techniques.
  • To compare the clinical validation and trial experience of serum markers, SPECT imaging, and MRI.
  • To determine the most suitable method for quantitating infarct size in acute myocardial infarction trials.

Main Methods:

  • Systematic review of English-language publications on infarct size measurement.

Related Experiment Videos

  • Evaluation of clinical validation data for serum markers, SPECT, and MRI.
  • Assessment of multicenter clinical trial experience for each modality.

    • Main Results:

    • Serum markers have theoretical and practical limitations; troponin shows promise but lacks extensive validation.
    • Technetium-99m sestamibi SPECT imaging demonstrates robust validity with five lines of evidence and extensive multicenter trial experience.
    • Magnetic resonance imaging shows promise but has limited clinical validation and no multicenter trial experience to date.

    Conclusions:

    • SPECT sestamibi imaging is the current gold standard for infarct size quantitation in acute myocardial infarction.
    • It is the most reliable technique for assessing treatment benefits in multicenter trials.
    • Further validation is needed for serum markers and MRI to reach the level of SPECT sestamibi imaging.